PIcc Cost EffectiveneSS and Safety of Infusional Therapy (PrInCESS)
Primary Purpose
Thrombosis, Infection
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Peripherally inserted central catheter (PICC)
Central venous catheter
Sponsored by
About this trial
This is an interventional other trial for Thrombosis focused on measuring Central Venous Catheters, Vascular Access Devices, Nursing, Cost Effectiveness, PICC
Eligibility Criteria
Inclusion Criteria:
- Patient above 5 years old,
- Hospitalized,
- With prescription of infusion therapy for 10 days or more of antibiotics, antineoplastics or other drugs with a pH lower than 5 or higher than 9 and / or osmolarity above 900 mOsm / l, parenteral nutrition or hypertonic solutions.
Exclusion Criteria:
- Insertion of the central catheter in emergency situations.
- Critical patient in the acute or terminal stage;
- Chronic renal disease stage IV or V and indication of hemodialysis;
- Pediatric patients with leukemia until the induction phase;
- Adult patients diagnosed with acute myeloid leukemia;
- Autologous and allogenic marrow transplantation;
- Upper limb with anatomical alteration, presence of arteriovenous fistula, axillary emptying or previous vascular procedure;
- Presence of skin changes in the area of the puncture, such as thrombophlebitis, dermatitis, cellulitis, burn among others;
- Patient using crutches or devices that require exertion or support in the upper limbs.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Peripherally inserted central catheter
Central venous catheter
Arm Description
The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
Outcomes
Primary Outcome Measures
infectious complications
bloodstream infection
thrombotic complications
radiographically-confirmed upper-extremity deep vein thrombosis
mechanical complications
chest X-ray
accidental removal
obstruction or accidental removal
Secondary Outcome Measures
Cost Effectiveness
reduction of the rates composite outcome of complications
Catheter occlusion: significant reduction of infusion flow or an impairment of blood back-flow;
Catheter damage, malposition and catheter migration.
Full Information
NCT ID
NCT03392831
First Posted
January 2, 2018
Last Updated
January 2, 2018
Sponsor
Hospital de Clinicas de Porto Alegre
1. Study Identification
Unique Protocol Identification Number
NCT03392831
Brief Title
PIcc Cost EffectiveneSS and Safety of Infusional Therapy
Acronym
PrInCESS
Official Title
Comparative Cost-Effectiveness and Safety of Infusional Therapy With Central Venous Catheters Versus Peripherally Inserted Central Catheters: a Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Unknown status
Study Start Date
April 2018 (Anticipated)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
December 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital de Clinicas de Porto Alegre
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Infusion therapy comprises the parenteral administration of solutions, through peripheral or central vascular access. Some solutions and drugs are highly irritating to the vascular endothelium and therefore cannot be administered in peripheral vessels, because increase the risk of phlebitis and/or tissue necrosis. Thus, the alternative is the central venous catheter (CVC) where the access can be by direct puncture of a central vessel or peripheral vessel puncture with progression of the catheter until central positioning, through a peripherally inserted central catheter (PICC).
We must take into account that indication, insertion, handling and maintenance must be balanced with risks, benefits and costs. The insertion and maintenance of both catheters are not free of complications. Among the most frequent are: Infection, thrombosis, lumen occlusion and accidental early removal of the catheter. This often implies in the need for new vascular access, impacting on morbidity and increased treatment costs.
The PICC has some advantages over CVC, for example: avoids repetitive punctures and consequently decreased handling/pain; a lower risk of infection; avoids the use of venous dissections; reduces the risks of pneumothorax/hemothorax; reduces the risk of infiltration, extravasation, necrosis tissue and chemical phlebitis. Further, the PICC can be used as a long-term catheter with easy handling in extra-hospital condition. All these advantages suggest that this technology offers lower cost to the health system and more benefits for patients. However, PICC is not available for use in infusion therapy in patients of the Brazilian public health system, except for neonates.
The available literature does not address cost-effectiveness studies of this technology in the international scope comparing the PICC versus CVC. And, similarly, we do not have studies conducted in Brazil to incorporate this technology into our public health system, based on its benefits and potential cost reduction.
In order to fill this gap, this study aims to test if the use of PICC in patients with infusional therapy equal or superior to 10 days (Intervention Group), will show a lower incidence in the outcomes (infection, thrombosis or mechanical complications), besides being more cost-effective when compared to the use of CVC of short stay (Control Group).
Detailed Description
Patient recruitment: Adult and pediatric patients will be included during hospitalization in the clinical/surgical units at the Hospital de Clínicas de Porto Alegre.
Variables of registry: Clinical data (diagnosis, reason for indication of catheter, site of insertion, vessel size, pharmacological treatment); Socio-demographic (age, sex, education, income); Ultrasonography (vessel evaluation); Radiography (to ensure the correct positioning of the catheter); economic variables (costs of all inputs used).
Data collection: All variables will be recorded in an instrument developed by the authors.
Statistical analysis: Continuous variables will be described using means and standard deviations or median and range in case of asymmetric distribution of data. Categorical variables will be presented using frequency distribution. Analyses will be conducted using chi-square and t tests for independent samples. P values <0.05 will be considered statistically significant. A Statistical Package for Social Sciences v.20.0 will be used. The Cox Regression Analysis and Log-rank test will compare the groups in relation to complication-free survival.
Cost-effectiveness analysis: The cost-effectiveness analysis will be measured by the incremental cost-effectiveness ratio (ICER), showed by the difference in cost between intervention and control group, divided by the difference in their effect. It represents the average incremental cost associated with 1 additional unit of the measure of effect. The cost-effectiveness analysis will be based on the cost estimate for insertion and maintenance of the catheter, including values of the inputs used, medicines, costs with professionals, surgical environment, laboratory and imaging exams.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thrombosis, Infection
Keywords
Central Venous Catheters, Vascular Access Devices, Nursing, Cost Effectiveness, PICC
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective Randomized Open Blinded End-Point (PROBE) study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
624 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Peripherally inserted central catheter
Arm Type
Experimental
Arm Description
The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
Arm Title
Central venous catheter
Arm Type
Active Comparator
Arm Description
The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
Intervention Type
Other
Intervention Name(s)
Peripherally inserted central catheter (PICC)
Intervention Description
The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
Intervention Type
Other
Intervention Name(s)
Central venous catheter
Intervention Description
The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
Primary Outcome Measure Information:
Title
infectious complications
Description
bloodstream infection
Time Frame
up to 30 days or the end of therapy
Title
thrombotic complications
Description
radiographically-confirmed upper-extremity deep vein thrombosis
Time Frame
up to 30 days or the end of therapy
Title
mechanical complications
Description
chest X-ray
Time Frame
up to 30 days or the end of therapy
Title
accidental removal
Description
obstruction or accidental removal
Time Frame
up to 30 days or need for another catheter
Secondary Outcome Measure Information:
Title
Cost Effectiveness
Description
reduction of the rates composite outcome of complications
Catheter occlusion: significant reduction of infusion flow or an impairment of blood back-flow;
Catheter damage, malposition and catheter migration.
Time Frame
up to 30 days or the end of therapy
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient above 5 years old,
Hospitalized,
With prescription of infusion therapy for 10 days or more of antibiotics, antineoplastics or other drugs with a pH lower than 5 or higher than 9 and / or osmolarity above 900 mOsm / l, parenteral nutrition or hypertonic solutions.
Exclusion Criteria:
Insertion of the central catheter in emergency situations.
Critical patient in the acute or terminal stage;
Chronic renal disease stage IV or V and indication of hemodialysis;
Pediatric patients with leukemia until the induction phase;
Adult patients diagnosed with acute myeloid leukemia;
Autologous and allogenic marrow transplantation;
Upper limb with anatomical alteration, presence of arteriovenous fistula, axillary emptying or previous vascular procedure;
Presence of skin changes in the area of the puncture, such as thrombophlebitis, dermatitis, cellulitis, burn among others;
Patient using crutches or devices that require exertion or support in the upper limbs.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eneida R Rabelo da Silva
Phone
+5551 33085226
Email
eneidarabelo@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Simone S Fantin
Phone
+555133598017
Email
sfantin@hcpa.edu.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carisi A Polanczyk
Organizational Affiliation
Federal University of Rio Grande do Sul - Faculty of Medicine
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Marco A Lumertz Saffi
Organizational Affiliation
Hospital de Clinicas de Porto Alegre
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jeruza L Neyeloff
Organizational Affiliation
Hospital de Clinicas de Porto Alegre
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
PIcc Cost EffectiveneSS and Safety of Infusional Therapy
We'll reach out to this number within 24 hrs